Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

  1. Where do you show that this challenge assay is done against the TB antigens?
  2. CP domain has developed a new standard variable called Test Condition Agent/CNDAGT, which is used to map represent stimulating agents, like the values in ASSYAG above, should this variable be added to LB? CP Specification
  3. Lastly, this  Interferon-Gamma Response Assay is a classic immunological test, should this be represented in LB?is it correct to map this to the LB domain?
    1. Can we model this in the IS domain, see example dataset below.
    2. Use NHOID to show the name of the bug (in this case M. tuberculosis.) to which the INFg response is evoked? If we model this test in IS, what about IFNG how do we distinguish it from the INFg test in lab. We need to Can we draw the line where if we are running a routine lab test looking for IFNg level it goes to LB vs. IFNg response test toward a specific, known bug then it goes to IS?
    3. If this test remains in LB, should NHOID be added to LB in order to show the name of the bug? I remember this being discussed by Jon/Bess when they worked on the TB TAUG.

...

Similarly if we were to model Jozef's request in IS for https://loinc.org/95971-8/ --- SARS CoV-2 stimulated gamma interferon [Presence] in Blood

...